chloral hydrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
586 302-17-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chloral hydrate
  • chloraldurat
  • nycoton
  • phaldrone
  • trichloroacetaldehyde hydrate
A hypnotic and sedative used in the treatment of INSOMNIA.
  • Molecular weight: 165.39
  • Formula: C2H3Cl3O2
  • CLOGP: 0.72
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: -0.58
  • ROTB: 1

Drug dosage:

DoseUnitRoute
1 g O
1 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 8300 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 86.37 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1840 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypomania 570.42 150.63 109 2096 6221 63480596
Jaundice cholestatic 548.45 150.63 108 2097 7216 63479601
Schizophrenia 527.03 150.63 110 2095 9842 63476975
Psychotic disorder 408.59 150.63 107 2098 25605 63461212
Hepatotoxicity 378.86 150.63 109 2096 36932 63449885
Blood bilirubin increased 378.58 150.63 109 2096 37031 63449786
Cholelithiasis 364.84 150.63 110 2095 43815 63443002
Hepatic enzyme increased 202.06 150.63 110 2095 202218 63284599
Asthma-chronic obstructive pulmonary disease overlap syndrome 194.55 150.63 37 2168 2024 63484793
Total lung capacity increased 190.34 150.63 37 2168 2273 63484544
Nasal polyps 154.91 150.63 37 2168 6002 63480815

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 80.02 54.10 15 517 1762 34954637
Respiratory failure 65.37 54.10 32 500 108540 34847859
Hypoventilation 64.59 54.10 14 518 3400 34952999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypomania 546.29 73.29 108 2622 7436 79734222
Jaundice cholestatic 502.93 73.29 108 2622 11176 79730482
Schizophrenia 479.94 73.29 110 2620 15330 79726328
Psychotic disorder 367.90 73.29 109 2621 41293 79700365
Cholelithiasis 346.20 73.29 110 2620 52554 79689104
Hepatotoxicity 344.76 73.29 109 2621 51243 79690415
Blood bilirubin increased 313.60 73.29 108 2622 66124 79675534
Hepatic enzyme increased 216.61 73.29 111 2619 182499 79559159
Total lung capacity increased 191.01 73.29 37 2693 2261 79739397
Asthma-chronic obstructive pulmonary disease overlap syndrome 178.54 73.29 37 2693 3184 79738474
Nasal polyps 148.27 73.29 37 2693 7290 79734368
Sarcoidosis 143.54 73.29 37 2693 8298 79733360
Rhinitis allergic 133.87 73.29 38 2692 12231 79729427
Condition aggravated 124.69 73.29 116 2614 501008 79240650
Cardiac murmur 120.07 73.29 37 2693 15787 79725871
Bronchiectasis 107.46 73.29 37 2693 22349 79719309
Vomiting 98.83 73.29 117 2613 665711 79075947
Pneumonia 92.98 73.29 113 2617 660133 79081525
Lung neoplasm malignant 78.11 73.29 31 2699 27761 79713897

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CC01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Aldehydes and derivatives
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:38869 general anaesthetic
CHEBI has role CHEBI:75771 Mus musculus metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Insomnia indication 193462001
Sedation off-label use 72641008
Proctitis contraindication 3951002 DOID:3127
Gastritis contraindication 4556007 DOID:4029
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Acute disease of cardiovascular system contraindication 128487001
Acute intermittent porphyria contraindication 234422006 DOID:3890




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle General anesthesia Indication
Cattle Sedation Indication
Horses General anesthesia Indication
Horses Sedation Indication

🐶 Veterinary products

ProductApplicantIngredients
Chloropent Zoetis Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.9 acidic
pKa2 13.19 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017726 VUID
N0000146094 NUI
D00265 KEGG_DRUG
2344 RXNORM
C0008161 UMLSCUI
CHEBI:28142 CHEBI
CHEMBL455917 ChEMBL_ID
DB01563 DRUGBANK_ID
D002697 MESH_DESCRIPTOR_UI
2707 PUBCHEM_CID
418M5916WG UNII
3870 MMSL
4404 MMSL
d00147 MMSL
001427 NDDF
273948005 SNOMEDCT_US
28748001 SNOMEDCT_US
4017726 VANDF

Pharmaceutical products:

None